Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Wölfel T[au]:

[Interface ward round]. Fischer MR et al. Dtsch Med Wochenschr. (2016)

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. Zhao F et al. Cancer Res. (2016)

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Landsberg J et al. Nature. (2012)

Search results

Items: 1 to 50 of 77

1.

Ward round competences in surgery and psychiatry - a comparative multidisciplinary interview study.

Vietz E, März E, Lottspeich C, Wölfel T, Fischer MR, Schmidmaier R.

BMC Med Educ. 2019 May 8;19(1):137. doi: 10.1186/s12909-019-1554-6.

2.

Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment.

Pieper N, Zaremba A, Leonardelli S, Harbers FN, Schwamborn M, Lübcke S, Schrörs B, Baingo J, Schramm A, Haferkamp S, Seifert U, Sucker A, Lennerz V, Wölfel T, Schadendorf D, Schilling B, Paschen A, Zhao F.

Oncoimmunology. 2018 Apr 18;7(8):e1450127. doi: 10.1080/2162402X.2018.1450127. eCollection 2018.

3.

Ward rounds in internal medicine: Validation of an Entrustable Professional Activity (EPA) observation checklist.

Schmelter V, März E, Adolf C, Wölfel TL, Lottspeich C, Fischer MR, Schmidmaier R.

GMS J Med Educ. 2018 May 15;35(2):Doc17. doi: 10.3205/zma001164. eCollection 2018.

4.

HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.

Schrörs B, Lübcke S, Lennerz V, Fatho M, Bicker A, Wölfel C, Derigs P, Hankeln T, Schadendorf D, Paschen A, Wölfel T.

Oncotarget. 2017 Apr 25;8(17):28312-28327. doi: 10.18632/oncotarget.16048.

5.

Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.

K Singh V, Werner S, Hackstein H, Lennerz V, Reiter A, Wölfel T, Damm-Welk C, Woessmann W.

Clin Exp Immunol. 2016 Oct;186(1):96-105. doi: 10.1111/cei.12842. Epub 2016 Aug 16.

6.

Medical ward round competence in internal medicine - an interview study towards an interprofessional development of an Entrustable Professional Activity (EPA).

Wölfel T, Beltermann E, Lottspeich C, Vietz E, Fischer MR, Schmidmaier R.

BMC Med Educ. 2016 Jul 11;16:174. doi: 10.1186/s12909-016-0697-y.

7.

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.

Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, Bicker A, Lindemann M, Roesch A, Gaudernack G, Stiller M, Becker JC, Lennerz V, Wölfel T, Schadendorf D, Griewank K, Paschen A.

Cancer Res. 2016 Aug 1;76(15):4347-58. doi: 10.1158/0008-5472.CAN-16-0008. Epub 2016 Jun 3.

8.

[Interface ward round].

Fischer MR, Wölfel T, Schmidmaier R.

Dtsch Med Wochenschr. 2016 Jan;141(1):28-31. doi: 10.1055/s-0041-108830. Epub 2015 Dec 28. German.

PMID:
26710200
9.

Exome Sequencing to Predict Neoantigens in Melanoma.

Pritchard AL, Burel JG, Neller MA, Hayward NK, Lopez JA, Fatho M, Lennerz V, Wölfel T, Schmidt CW.

Cancer Immunol Res. 2015 Sep;3(9):992-8. doi: 10.1158/2326-6066.CIR-15-0088. Epub 2015 Jun 5.

10.

[Immune oncology in focus].

Wölfel T, Becker JC, Schmitt M.

Onkologie. 2013;36 Suppl 4:7-11. doi: 10.1159/000350921. Epub 2013 May 7. German. No abstract available.

11.

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.

Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, Tüting T.

Nature. 2012 Oct 18;490(7420):412-6. doi: 10.1038/nature11538. Epub 2012 Oct 10.

PMID:
23051752
12.

The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation.

Schuchmann M, Meyer RG, Distler E, von Stebut E, Kuball J, Schnürer E, Wölfel T, Theobald M, Konur A, Gregor S, Schreiner O, Huber C, Galle PR, Otto G, Herr W.

Am J Transplant. 2008 Nov;8(11):2434-44. doi: 10.1111/j.1600-6143.2008.02401.x.

13.

Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.

Tschiedel S, Gentilini C, Lange T, Wölfel C, Wölfel T, Lennerz V, Stevanovic S, Rammensee HG, Huber C, Cross M, Niederwieser D.

Leukemia. 2008 Aug;22(8):1542-50. doi: 10.1038/leu.2008.107. Epub 2008 May 22.

PMID:
18496563
14.

Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.

Distler E, Wölfel C, Köhler S, Nonn M, Kaus N, Schnürer E, Meyer RG, Wehler TC, Huber C, Wölfel T, Hartwig UF, Herr W.

Exp Hematol. 2008 Apr;36(4):451-63. doi: 10.1016/j.exphem.2007.12.011. Epub 2008 Feb 8.

PMID:
18261837
15.

Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells.

Javorovic M, Wilde S, Zobywalski A, Noessner E, Lennerz V, Wölfel T, Schendel DJ.

J Immunother. 2008 Jan;31(1):52-62.

PMID:
18157012
16.

Dissection and molecular analysis of alloreactive CD8+ T cell responses in allogeneic haematopoietic stem cell transplantation.

Wölfel C, Lennerz V, Lindemann E, Hess G, Derigs HG, Huber C, Herr W, Wölfel T.

Cancer Immunol Immunother. 2008 Jun;57(6):849-57. Epub 2007 Nov 15.

PMID:
18004563
17.

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.

Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T, van der Burg SH.

Cancer Immunol Immunother. 2008 Mar;57(3):289-302. Epub 2007 Aug 25.

18.

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.

Meyer RG, Korn S, Micke P, Becker K, Huber C, Wölfel T, Buhl R.

Lung Cancer. 2007 Oct;58(1):88-94. Epub 2007 Jun 27.

PMID:
17599645
19.

Rapid identification of an HLA-B*1501-restricted vaccinia peptide antigen.

Meyer RG, Graf C, Britten CM, Huber C, Wölfel T.

Vaccine. 2007 Jun 11;25(24):4715-22. Epub 2007 Apr 25.

PMID:
17499403
20.

A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells.

Graf C, Heidel F, Tenzer S, Radsak MP, Solem FK, Britten CM, Huber C, Fischer T, Wölfel T.

Blood. 2007 Apr 1;109(7):2985-8.

21.

Rapid molecular dissection of viral and bacterial immunomes.

Sahin U, Türeci O, Graf C, Meyer RG, Lennerz V, Britten CM, Dumrese C, Scandella E, Wölfel T, Ludewig B.

Eur J Immunol. 2006 Apr;36(4):1049-57.

22.

Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes.

Chromik J, Schnürer E, Georg Meyer R, Wehler T, Tüting T, Wölfel T, Huber C, Herr W.

J Immunol Methods. 2006 Jan 20;308(1-2):77-89. Epub 2005 Nov 28.

PMID:
16336973
23.

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.

Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T.

Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8. Epub 2005 Oct 24.

24.

Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2.

Steitz J, Britten CM, Wölfel T, Tüting T.

Cancer Immunol Immunother. 2006 Mar;55(3):246-53. Epub 2005 Aug 13.

PMID:
16133114
25.

Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin.

Steitz J, Büchs S, Tormo D, Ferrer A, Wenzel J, Huber C, Wölfel T, Barbacid M, Malumbres M, Tüting T.

Int J Cancer. 2006 Jan 15;118(2):373-80.

26.
27.

Identification of T cell epitopes by the use of rapidly generated mRNA fragments.

Britten CM, Meyer RG, Graf C, Huber C, Wölfel T.

J Immunol Methods. 2005 Apr;299(1-2):165-75. Epub 2005 Mar 31.

PMID:
15914199
28.

Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.

Zhang Y, Sun Z, Nicolay H, Meyer RG, Renkvist N, Stroobant V, Corthals J, Carrasco J, Eggermont AM, Marchand M, Thielemans K, Wölfel T, Boon T, van der Bruggen P.

J Immunol. 2005 Feb 15;174(4):2404-11.

29.

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, Wölfel T.

Cancer Immunol Immunother. 2005 May;54(5):453-67. Epub 2004 Dec 31.

PMID:
15627214
30.

CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.

Dörrschuck A, Schmidt A, Schnürer E, Glückmann M, Albrecht C, Wölfel C, Lennerz V, Lifke A, Di Natale C, Ranieri E, Gesualdo L, Huber C, Karas M, Wölfel T, Herr W.

Blood. 2004 Oct 15;104(8):2591-9. Epub 2004 Jul 1.

31.

The use of clonal mRNA as an antigenic format for the detection of antigen-specific T lymphocytes in IFN-gamma ELISPOT assays.

Britten CM, Meyer RG, Frankenberg N, Huber C, Wölfel T.

J Immunol Methods. 2004 Apr;287(1-2):125-36.

PMID:
15099761
32.

Immunotherapy of cancer: from vision to standard clinical practice.

Huber CH, Wölfel T.

J Cancer Res Clin Oncol. 2004 Jul;130(7):367-74. Review.

PMID:
15067541
33.

Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.

Kuball J, Schuler M, Antunes Ferreira E, Herr W, Neumann M, Obenauer-Kutner L, Westreich L, Huber C, Wölfel T, Theobald M.

Gene Ther. 2002 Jul;9(13):833-43.

34.

Identification of HLA-A*0201-restricted T cell epitopes derived from the novel overexpressed tumor antigen calcium-activated chloride channel 2.

Konopitzky R, König U, Meyer RG, Sommergruber W, Wölfel T, Schweighoffer T.

J Immunol. 2002 Jul 1;169(1):540-7.

35.

[T-cell therapy in oncology. Therapeutic vaccination, allogeneic blood stem cell transplantation and adoptive T-cell transfer].

Kuball J, Derigs HG, Wölfel T.

Dtsch Med Wochenschr. 2002 Apr 5;127(14):755-62. Review. German. No abstract available.

PMID:
11935475
36.

The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.

Britten CM, Meyer RG, Kreer T, Drexler I, Wölfel T, Herr W.

J Immunol Methods. 2002 Jan 1;259(1-2):95-110.

PMID:
11730845
37.

Therapeutic vaccination against T-cell-defined tumor antigens.

Wölfel T, Huber C.

Onkologie. 2001 Feb;24(1):9. No abstract available.

38.

Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope.

Wölfel C, Drexler I, Van Pel A, Thres T, Leister N, Herr W, Sutter G, Huber C, Wölfel T.

Int J Cancer. 2000 Nov 1;88(3):432-8.

39.

Consequences of antigen self-presentation by tumor-specific cytotoxic T cells.

Staege MS, Schneider J, Eulitz M, Scholz S, Bornkamm GW, Wölfel T, Reske-Kunz AB.

Immunobiology. 2000 Jan;201(3-4):332-46.

PMID:
10776790
40.

A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes.

Morel S, Ooms A, Van Pel A, Wölfel T, Brichard VG, van der Bruggen P, Van den Eynde BJ, Degiovanni G.

Int J Cancer. 1999 Dec 10;83(6):755-9.

41.
42.
43.

Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B.

Löhr HF, Krug S, Herr W, Weyer S, Schlaak J, Wölfel T, Gerken G, Meyer zum Büschenfelde KH.

Liver. 1998 Dec;18(6):405-13.

PMID:
9869395
44.
45.
46.

Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.

Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, Steinle A, Wolfel T, Lienard D, Brichard V, van Pel A, Jotereau F, Cerottini JC.

J Immunol. 1997 Sep 1;159(5):2366-74.

PMID:
9278327
47.

The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens.

Herr W, Linn B, Leister N, Wandel E, Meyer zum Büschenfelde KH, Wölfel T.

J Immunol Methods. 1997 Apr 25;203(2):141-52.

PMID:
9149807
48.

Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma.

Bernhard H, Maeurer MJ, Jäger E, Wölfel T, Schneider J, Karbach J, Seliger B, Huber C, Storkus WS, Lotze MT, Meyer zum Büschenfelde KH, Knuth A.

Scand J Immunol. 1996 Sep;44(3):285-92.

PMID:
8795723
49.

Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.

Herr W, Schneider J, Lohse AW, Meyer zum Büschenfelde KH, Wölfel T.

J Immunol Methods. 1996 May 27;191(2):131-42.

PMID:
8666832
50.

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH.

J Exp Med. 1996 Feb 1;183(2):527-34.

Supplemental Content

Loading ...
Support Center